IL201474A - Imitation smack diazo in bicycles, medical preparations and kits containing them and their uses - Google Patents
Imitation smack diazo in bicycles, medical preparations and kits containing them and their usesInfo
- Publication number
- IL201474A IL201474A IL201474A IL20147409A IL201474A IL 201474 A IL201474 A IL 201474A IL 201474 A IL201474 A IL 201474A IL 20147409 A IL20147409 A IL 20147409A IL 201474 A IL201474 A IL 201474A
- Authority
- IL
- Israel
- Prior art keywords
- kits
- pharmaceutical compositions
- smac mimetics
- diazo bicyclic
- bicyclic smac
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92334807P | 2007-04-13 | 2007-04-13 | |
| PCT/US2008/060215 WO2008128171A2 (en) | 2007-04-13 | 2008-04-14 | Diazo bicyclic smac mimetics and the uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL201474A0 IL201474A0 (en) | 2010-05-31 |
| IL201474A true IL201474A (en) | 2015-11-30 |
Family
ID=39864640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL201474A IL201474A (en) | 2007-04-13 | 2009-10-12 | Imitation smack diazo in bicycles, medical preparations and kits containing them and their uses |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8278293B2 (enExample) |
| EP (1) | EP2139490B1 (enExample) |
| JP (1) | JP5416089B2 (enExample) |
| KR (1) | KR101081685B1 (enExample) |
| CN (1) | CN101686981B (enExample) |
| AU (1) | AU2008240119B2 (enExample) |
| BR (1) | BRPI0810522B8 (enExample) |
| CA (1) | CA2683318C (enExample) |
| CY (1) | CY1115735T1 (enExample) |
| DK (1) | DK2139490T3 (enExample) |
| EA (1) | EA017797B1 (enExample) |
| ES (1) | ES2504216T3 (enExample) |
| HR (1) | HRP20140885T1 (enExample) |
| HU (1) | HUE024142T2 (enExample) |
| IL (1) | IL201474A (enExample) |
| MX (1) | MX2009011069A (enExample) |
| NZ (1) | NZ580468A (enExample) |
| PL (1) | PL2139490T3 (enExample) |
| PT (1) | PT2139490E (enExample) |
| SI (1) | SI2139490T1 (enExample) |
| WO (1) | WO2008128171A2 (enExample) |
| ZA (1) | ZA200907055B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| RU2418807C2 (ru) | 2005-10-25 | 2011-05-20 | Аегера Терапьютикс Инк. | Соединения, связывающие bir домены iap |
| TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| HRP20140885T1 (hr) * | 2007-04-13 | 2014-11-21 | The Regents Of The University Of Michigan | Diazo bicikliäśki smac mimetici i njihove primjene |
| WO2011050068A2 (en) * | 2009-10-23 | 2011-04-28 | The Regents Of The University Of Michigan | Bivalent diazo bicyclic smac mimetics and the uses thereof |
| WO2011057099A2 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| MX340870B (es) | 2010-02-12 | 2016-07-27 | Pharmascience Inc | Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus. |
| WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| ES2654623T3 (es) * | 2012-08-23 | 2018-02-14 | The Regents Of The University Of Michigan | Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan |
| CA2896577C (en) | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2013399606B2 (en) | 2013-09-09 | 2016-09-22 | Halliburton Energy Services, Inc. | Activation of set-delayed cement compositions by retarder exchange |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3151920B1 (en) | 2014-06-04 | 2025-08-06 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| CA3020792A1 (en) | 2016-04-20 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising ripk2 inhibitors |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3535265A4 (en) | 2016-11-01 | 2020-07-08 | Arvinas, Inc. | PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE |
| WO2018102725A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| EP3558994A4 (en) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| EP4310496A3 (en) | 2017-07-12 | 2024-12-04 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
| MX2020004074A (es) | 2017-10-19 | 2020-10-16 | Debiopharm Int Sa | Producto de combinacion para el tratamiento de cancer. |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| US11028088B2 (en) | 2018-03-10 | 2021-06-08 | Yale University | Modulators of BTK proteolysis and methods of use |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| WO2020023851A1 (en) | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| CN112533898A (zh) | 2018-07-31 | 2021-03-19 | 日商泛美克斯股份有限公司 | 杂环化合物 |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| IL319737A (en) | 2018-09-07 | 2025-05-01 | Arvinas Operations Inc | Polycyclic compounds and methods for targeted reduction of rapidly accelerating fibrosarcoma polypeptides |
| EP3866801A4 (en) | 2018-10-16 | 2022-11-09 | Dana-Farber Cancer Institute, Inc. | DEGRADER OF WILD-TYPE AND MUTANT FORMS OF LRRK2 |
| US20220016079A1 (en) | 2018-11-26 | 2022-01-20 | Debiopharm International S.A. | Combination treatment of hiv infections |
| US10870663B2 (en) | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| US20220096436A1 (en) | 2019-01-17 | 2022-03-31 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| EP3947368B1 (en) | 2019-04-04 | 2025-09-03 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| CN110028508B (zh) * | 2019-05-16 | 2021-05-28 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂 |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| US20220402935A1 (en) | 2019-07-31 | 2022-12-22 | Fimecs, Inc. | Heterocyclic compound |
| ES3061133T3 (en) | 2019-08-26 | 2026-03-31 | Arvinas Operations Inc | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| WO2021058794A1 (en) * | 2019-09-25 | 2021-04-01 | Debiopharm International S.A. | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| EP4093394A1 (en) * | 2020-01-20 | 2022-11-30 | Astrazeneca AB | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| WO2022198196A1 (en) | 2021-03-15 | 2022-09-22 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| WO2024022275A1 (zh) | 2022-07-29 | 2024-02-01 | 苏州科睿思制药有限公司 | Xevinapant的晶型及其制备方法和用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN118027138A (zh) * | 2022-11-07 | 2024-05-14 | 南京中澳转化医学研究院有限公司 | 吡啶酮类化合物及其制备方法、药物组合物和应用 |
| AR131299A1 (es) * | 2022-12-09 | 2025-03-05 | Debiopharm Int Sa | Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2026006700A1 (en) * | 2024-06-28 | 2026-01-02 | Regents Of The University Of Michigan | Pyrrolo[1,2-a]-azocine analogues as iap antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| CA2462200A1 (en) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| MXPA06008095A (es) | 2004-01-16 | 2007-03-28 | Univ Michigan | Mimeticos de smac conformacionalmente restringidos y sus usos. |
| WO2006010118A2 (en) * | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| WO2006010119A2 (en) | 2004-07-09 | 2006-01-26 | Michael Norris | Cargo retaining device for use in vehicle cargo storage areas |
| HRP20141253T1 (en) | 2006-05-05 | 2015-03-13 | The Regents Of The Universitiy Of Michigan | Intermediates for the preparation of bivalent smac mimetics |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| HRP20140885T1 (hr) * | 2007-04-13 | 2014-11-21 | The Regents Of The University Of Michigan | Diazo bicikliäśki smac mimetici i njihove primjene |
| JP5887134B2 (ja) * | 2008-04-11 | 2016-03-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ヘテロアリールによって置換されている二環式のＳｍａｃの模倣物 |
| US8625740B2 (en) * | 2011-04-14 | 2014-01-07 | Morpho Detection, Inc. | System and method for correcting X-ray diffraction profiles |
-
2008
- 2008-04-14 HR HRP20140885AT patent/HRP20140885T1/hr unknown
- 2008-04-14 SI SI200831285T patent/SI2139490T1/sl unknown
- 2008-04-14 CN CN2008800186484A patent/CN101686981B/zh not_active Expired - Fee Related
- 2008-04-14 MX MX2009011069A patent/MX2009011069A/es active IP Right Grant
- 2008-04-14 BR BRPI0810522A patent/BRPI0810522B8/pt not_active IP Right Cessation
- 2008-04-14 AU AU2008240119A patent/AU2008240119B2/en not_active Ceased
- 2008-04-14 ES ES08745750.3T patent/ES2504216T3/es active Active
- 2008-04-14 PT PT87457503T patent/PT2139490E/pt unknown
- 2008-04-14 KR KR1020097023384A patent/KR101081685B1/ko active Active
- 2008-04-14 DK DK08745750.3T patent/DK2139490T3/da active
- 2008-04-14 EA EA200901400A patent/EA017797B1/ru unknown
- 2008-04-14 US US12/159,249 patent/US8278293B2/en active Active
- 2008-04-14 NZ NZ580468A patent/NZ580468A/en not_active IP Right Cessation
- 2008-04-14 CA CA2683318A patent/CA2683318C/en active Active
- 2008-04-14 WO PCT/US2008/060215 patent/WO2008128171A2/en not_active Ceased
- 2008-04-14 EP EP08745750.3A patent/EP2139490B1/en active Active
- 2008-04-14 JP JP2010503269A patent/JP5416089B2/ja active Active
- 2008-04-14 PL PL08745750T patent/PL2139490T3/pl unknown
- 2008-04-14 HU HUE08745750A patent/HUE024142T2/en unknown
-
2009
- 2009-10-09 ZA ZA2009/07055A patent/ZA200907055B/en unknown
- 2009-10-12 IL IL201474A patent/IL201474A/en active IP Right Grant
-
2012
- 2012-07-25 US US13/557,804 patent/US8664212B2/en not_active Expired - Fee Related
-
2014
- 2014-09-29 CY CY20141100792T patent/CY1115735T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL201474A0 (en) | Diazo bicyclic smac mimetics and the uses thereof | |
| ZA200809496B (en) | Bivalent smac mimetics and the uses thereof | |
| IL192631A (en) | A drug containing an isolated antibody or a functional portion thereof, pharmaceutical preparations and a kit containing it | |
| IL198509A0 (en) | Azaindole derivatives, compositions containing the same and uses thereof | |
| IL210722A0 (en) | Benzazepine derivatives, compositions comprising the same and uses thereof | |
| IL204211A (en) | 2epha antidote, a drug containing it and its uses | |
| AU2007233035A8 (en) | Substituted bicyclic derivative and use thereof | |
| EP2033942A4 (en) | COMPOSITION FOR FORMING AN INTERMEDIATE LAYER FOR COMPOSITE GLASS, INTERMEDIATE LAYER FOR COMPOSITE GLASS AND COMPOSITE GLASS | |
| IL196292A0 (en) | Csf3r polypeptides, their preparation and uses thereof | |
| GB2435896B (en) | Double glazed units | |
| AU2007100528A4 (en) | Illuminant bottle | |
| HK1152309A (en) | Heteroaryl-substituted bicyclic smac mimetics and the uses thereof | |
| AU2013206191B2 (en) | Thioninium compounds and their use | |
| AU2007903401A0 (en) | Bicyclic pyrimidinodes and uses thereof (3) | |
| EM06327990003S (mt) | Sedili | |
| EM06327990008S (cs) | Sedací nábytek | |
| EM06327990006S (et) | Istmed | |
| EM06327990002S (et) | Istmed | |
| EM06111160002S (mt) | Sedili | |
| EM06327990005S (da) | Siddeelementer | |
| EM06046650001S (fr) | Meubles pour s'asseoir | |
| EM06327990007S (sk) | Nábytok na sedenie | |
| EM06046650002S (sl) | Sedeži | |
| EM06111160006S (da) | Siddeelementer | |
| EM06111160007S (et) | Istmed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |